Abstract:Abstract Background Multiple breast cancer gene expression profiles have been developed that appear to provide similar abilities to predict outcome and may outperform clinical-pathologic criteria; however, the extent to which seemingly disparate profiles provide additive prognostic information is not known, nor do we know whether prognostic profiles perform equally across clinically defined breast cancer subtypes. We evaluated whether combining the prognostic powers of standard breast cancer clinical variables with a large set of gene expression signatures could improve on our ability to predict patient outcomes. Methods Using clinical-pathological variables and a collection of 323 gene expression "modules", including 115 previously published signatures, we build multivariate Cox proportional hazards models using a dataset of 550 node-negative systemically untreated breast cancer patients. Models predictive of pathological complete response (pCR) to neoadjuvant chemotherapy were also built using this approach. Results We identified statistically significant prognostic models for relapse-free survival (RFS) at 7 years for the entire population, and for the subgroups of patients with ER-positive, or Luminal tumors. Furthermore, we found that combined models that included both clinical and genomic parameters improved prognostication compared with models with either clinical or genomic variables alone. Finally, we were able to build statistically significant combined models for pathological complete response (pCR) predictions for the entire population. Conclusions Integration of gene expression signatures and clinical-pathological factors is an improved method over either variable type alone. Highly prognostic models could be created when using all patients, and for the subset of patients with lymph node-negative and ER-positive breast cancers. Other variables beyond gene expression and clinical-pathological variables, like gene mutation status or DNA copy number changes, will be needed to build robust prognostic models for ER-negative breast cancer patients. This combined clinical and genomics model approach can also be used to build predictors of therapy responsiveness, and could ultimately be applied to other tumor types.

Integrating Biological Knowledge with Gene Expression Profiles for Survival Prediction of Cancer

Identification of Gene Expression Pattern Related to Breast Cancer Survival Using Integrated TCGA Datasets and Genomic Tools.

An Integrated Model of Clinical Information and Gene Expression for Prediction of Survival in Ovarian Cancer Patients

Assessing the Effect of Data Integration on Predictive Ability of Cancer Survival Models

Multimodal Survival Ensemble Network: Integrating Genomic and Histopathological Insights for Enhanced Cancer Prognosis.

Toward Precision Breast Cancer Survival Prediction Utilizing Combined Whole Genome-Wide Expression and Somatic Mutation Analysis

Gene Expression based Survival Prediction for Cancer Patients: A Topic Modeling Approach

Novel Model for Comprehensive Assessment of Robust Prognostic Gene Signature in Ovarian Cancer Across Different Independent Datasets

Importance of gene expression signatures in pancreatic cancer prognosis and the establishment of a prediction model

Integrative survival analysis of breast cancer with gene expression and DNA methylation data

Deep Biological Pathway Informed Pathology-Genomic Multimodal Survival Prediction

Strategies to integrate multi-omics data for patient survival prediction

Towards key genes identification for breast cancer survival risk with neural network models

Tumor Microenvironment-Related Multigene Prognostic Prediction Model for Breast Cancer

Cancer prediction with gene expression profiling and differential evolution

High Accordance in Prognosis Prediction of Colorectal Cancer Across Independent Datasets by Multi-Gene Module Expression Profiles

Enhancing Breast Cancer Survival Prognosis Through Omic and Non-Omic Data Integration

Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures

Predicting features of breast cancer with gene expression patterns

Identification of Pan-Cancer Prognostic Biomarkers Through Integration of Multi-Omics Data